LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | GSK 690693 | 10 | uM | LJP5 | 72 | hr | 2543 | 4505 | 5752 | 0.7832 | 0.6251 |
| SK-BR-3 | SNS-032 | 0.04 | uM | LJP6 | 72 | hr | 2543 | 4001 | 5418 | 0.7401 | 0.5197 |
| SK-BR-3 | SNS-032 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 1573 | 5418 | 0.2907 | -0.3562 |
| SK-BR-3 | SNS-032 | 0.37 | uM | LJP6 | 72 | hr | 2543 | 1260 | 5418 | 0.2327 | -0.4750 |
| SK-BR-3 | SNS-032 | 1.11 | uM | LJP6 | 72 | hr | 2543 | 1181 | 5418 | 0.2178 | -0.5056 |
| SK-BR-3 | SNS-032 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 1077 | 5418 | 0.1991 | -0.5453 |
| SK-BR-3 | SNS-032 | 10 | uM | LJP6 | 72 | hr | 2543 | 993 | 5418 | 0.1835 | -0.5780 |
| SK-BR-3 | Afatinib | 0.04 | uM | LJP6 | 72 | hr | 2543 | 1536 | 5418 | 0.2839 | -0.3702 |
| SK-BR-3 | Afatinib | 0.12 | uM | LJP6 | 72 | hr | 2543 | 1683 | 5418 | 0.3110 | -0.3150 |
| SK-BR-3 | Afatinib | 0.37 | uM | LJP6 | 72 | hr | 2543 | 1713 | 5418 | 0.3162 | -0.3045 |
| SK-BR-3 | Afatinib | 1.11 | uM | LJP6 | 72 | hr | 2543 | 1745 | 5418 | 0.3222 | -0.2923 |
| SK-BR-3 | Afatinib | 3.33 | uM | LJP6 | 72 | hr | 2543 | 1938 | 5418 | 0.3580 | -0.2206 |
| SK-BR-3 | Afatinib | 10 | uM | LJP6 | 72 | hr | 2543 | 1731 | 5418 | 0.3198 | -0.2973 |
| SK-BR-3 | GSK1904529A | 0.04 | uM | LJP6 | 72 | hr | 2543 | 4735 | 5418 | 0.8753 | 0.7723 |
| SK-BR-3 | GSK1904529A | 0.12 | uM | LJP6 | 72 | hr | 2543 | 4993 | 5418 | 0.9226 | 0.8596 |
| SK-BR-3 | GSK1904529A | 0.37 | uM | LJP6 | 72 | hr | 2543 | 5413 | 5418 | 0.9998 | 1.0012 |
| SK-BR-3 | GSK1904529A | 1.11 | uM | LJP6 | 72 | hr | 2543 | 5536 | 5418 | 1.0226 | 1.0431 |
| SK-BR-3 | GSK1904529A | 3.33 | uM | LJP6 | 72 | hr | 2543 | 5595 | 5418 | 1.0331 | 1.0618 |
| SK-BR-3 | GSK1904529A | 10 | uM | LJP6 | 72 | hr | 2543 | 5645 | 5418 | 1.0426 | 1.0798 |
| SK-BR-3 | Linsitinib | 0.04 | uM | LJP5 | 72 | hr | 2543 | 4345 | 5752 | 0.7554 | 0.5758 |
| SK-BR-3 | Linsitinib | 0.12 | uM | LJP5 | 72 | hr | 2543 | 4923 | 5752 | 0.8558 | 0.7521 |
| SK-BR-3 | Linsitinib | 0.37 | uM | LJP5 | 72 | hr | 2543 | 5254 | 5752 | 0.9135 | 0.8519 |
| SK-BR-3 | Linsitinib | 1.11 | uM | LJP5 | 72 | hr | 2543 | 5013 | 5752 | 0.8715 | 0.7793 |
| SK-BR-3 | Linsitinib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 4635 | 5752 | 0.8058 | 0.6647 |
| SK-BR-3 | Linsitinib | 10 | uM | LJP5 | 72 | hr | 2543 | 4150 | 5752 | 0.7215 | 0.5158 |